Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

37
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
37
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

50
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
50
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Correction: Working to Increase Stability through Exercise (WISE): screening, recruitment, and baseline characteristics.

Trials·2026
Same author

Conducting multicenter trials through the trial innovation network comprehensive consultation.

Contemporary clinical trials·2026
Same author

Who Is Still Paying Out-of-Pocket for Their IUDs Despite the ACA Contraceptive Coverage Requirement? Analysis of a Large National Cohort Using Claims Data.

Women's health issues : official publication of the Jacobs Institute of Women's Health·2026
Same author

Digital and community-engaged approaches to improve research participant recruitment - Advice from forty convened experts.

Journal of clinical and translational science·2026
Same author

Trends in Blood Pressure Control During the COVID-19 Pandemic: A Study of 17 US Health Systems in the National Patient-Centered Clinical Research Network Blood Pressure Control Laboratory.

Journal of the American Heart Association·2026
Same author

Factors and outcomes associated with early and deferred gastrostomy tube placement in acute ischemic stroke patients in the United States.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same journal

The cardiovascular risk continuum: Continuing to challenge the primary and secondary prevention dichotomy.

American journal of preventive cardiology·2026
Same journal

Cardiovascular event rate modifies response to pharmacologic LDL-C lowering in primary prevention: implications of a systematic review and meta-analysis for clinical practice.

American journal of preventive cardiology·2026
Same journal

The impact of bempedoic acid on cardiovascular events across the spectrum of kidney function, a CLEAR Outcomes trial secondary analysis.

American journal of preventive cardiology·2026
Same journal

Preconception cardiometabolic health and adverse pregnancy outcomes in hispanic and latina women: Expanding the prevention window.

American journal of preventive cardiology·2026
Same journal

Resistance training in older adults: are the gains worth the strain?

American journal of preventive cardiology·2026
Same journal

The ABCs of cardiovascular disease prevention: communicating what we know in 2026.

American journal of preventive cardiology·2026
查看所有相关文章

相关实验视频

Updated: Sep 9, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

根据ACC/AHA指导方针进行高风险的ASCVD初级和二级预防的实际处方: 根据ACC/AHA指导方针进行降脂治疗的实际处方

Jonathan Arnold1, Deeksha Acharya2, Hetal Boricha2

  • 1Department of Medicine, University of Pittsburgh School of Medicine, USA.

American journal of preventive cardiology
|September 2, 2025
PubMed
概括
此摘要是机器生成的。

降脂疗法对于预防动脉样硬化心血管疾病至关重要. 然而,实际数据显示,许多患者没有接受指导方针推的高强度他类药物治疗,这表明需要改进ASCVD风险降低策略.

关键词:
心血管疾病药物处方使用毒品甲基酸降解酶抑制剂高胆固醇血症低低谷蛋白胆固醇降脂疗法实践模式主要预防现实世界中的证据二次预防类药物

更多相关视频

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.4K

相关实验视频

Last Updated: Sep 9, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.4K

科学领域:

  • 心脏病学
  • 预防医学
  • 医疗服务研究

背景情况:

  • 降脂治疗 (LLT) 对于预防动脉样硬化心血管疾病 (ASCVD) 是必不可少的.
  • 指导方针建议使用他类药物进行二次和高风险的初级ASCVD预防.
  • 之前的研究表明,在某些群体和环境中,对指南的遵守程度低于最佳水平.

研究的目的:

  • 描述现实世界的LLT处方模式.
  • 评估不同患者群体和多个美国卫生系统的遵守指南.

主要方法:

  • 来自PaTH临床研究网络的电子健康记录的横截面分析.
  • 包括三个群体:ASCVD,没有ASCVD的糖尿病 (DM) 和高LDL-C (>190 mg/dL).
  • 评估患者特征,护理模式,脂质水平和在每个队列和整个卫生系统中记录的LLT.

主要成果:

  • 对240,625名ASCVD,113,662名DM和11,276名高LDL-C患者的分析.
  • 低达标的LDL-C (<70 mg/ dL):ASCVD患者的比例为37%,DM患者的比例为27%.
  • 高强度他类药物的低最佳使用:34%在ASCVD中,19%在DM中,16%在高LDL-C队列中.
  • 在医疗系统之间观察到LLT处方模式的显著变化.

结论:

  • 大多数符合ASCVD预防标准的患者没有得到记录的高强度他类药物治疗.
  • 很大一部分患者没有达到建议的LDL- C目标.
  • 跨卫生系统的护理变化突出了改善准则遵守和降低ASCVD风险的机会.